Open Access

Analysis Of Selected Genetic Traits, Phenotypes, And The Epidemiological Threat Of Enterococcus Bacteria Resistant To Vancomycin


Cite

Fig. 1.

The scheme of the gene cluster structure determining phenotypes VanA, VanB, VanD, VanG i VanM (based on [41, 47, 49, 52]).
The scheme of the gene cluster structure determining phenotypes VanA, VanB, VanD, VanG i VanM (based on [41, 47, 49, 52]).

Fig. 2.

Vancomycin resistance among E. faecium and E. faecalis strains isolated from blood samples of the Polish patients between 2010 and 2015 [67].
Vancomycin resistance among E. faecium and E. faecalis strains isolated from blood samples of the Polish patients between 2010 and 2015 [67].

Characterization of vancomycin-resistant Enterococcus phenotypes

Phenotype Vancomycin MIC (mg/L) Teicoplanin MIC (mg/L) Modification Localization Transfer capibility Expression Major species
VanA 64–1000 16–512 d-Ala-d-Lac Plasmid or chromosome yes induced E. faecalis, E. faecium
VanB 4–1000 0.5–1 d-Ala-d-Lac Plasmid or chromosome yes induced E. faecalis, E. faecium
VanC 2–32 0.5–1 d-Ala-d-Ser chromosome no Constitutive or induced E. gallinarum, E. casseliflavus
VanD 64–128 4–64 d-Ala-d-Lac Plasmid or chromosome no Constitutive or induced E. faecalis, E. faecium
VanE 8–32 0.5 d-Ala-d-Ser chromosome no induced E. faecalis
VanG ≤ 16 wrażliwy d-Ala-d-Ser chromosome yes induced E. faecalis
VanL 8 ≤ 0.5 d-Ala-d-Ser chromosome no induced E. faecalis
VanM > 256 96 d-Ala-d-Lac Plasmid or chromosome yes induced E. faecium
VanN 16 ≤ 0.5 d-Ala-d-Ser plasmid yes constitutive E. faecium

Percentages of vancomycin-resistant Enterococcus faecium isolates in the European countries between 2012 and 2015 (data according to [77])

Percentages of vancomycin-resistant Enterococcus faecium isolates 2012 2015
Below 1% Iceland, Norway, Sweden, Finland, Estonia, the Netherlands, France, Slovenia, Croatia, Bulgaria Iceland, Norway, Sweden, Finland, Estonia, France, Belgium
1–5% Spain, Belgium, Denmark, Austria, Slovakia, Hungary, Romania Spain, Denmark, the Netherlands, Austria, Slovenia
5–10% Latvia, Lithuania, Poland, Italy Czechia (Czech Republic)
10–25% Great Britain, Portugal, Germany, Czechia (Czech Republic), Greece, Cyprus Great Britain, Portugal, Germany, Poland, Latvia, Lithuania, Slovakia, Hungary, Italy, Bulgaria, Greece
25–50% Ireland Ireland, Croatia, Romania, Cyprus
over 50%

The specification of VRE isolates number and the percentages of all alarming factors at 195 Polish hospitals between 2012 and 2016 (data according to [71])

Year No. of isolates Percentage of all alarming factors
2016 50 1.14%
2015 34 0.81%
2014 No data No data
2013 18 0.44%
2012 11 0.33%

Resistance to the selected antibiotics of VRE isolates collected from 7 different hospitals

Enterococci strains Drug used MIC (μg/ml) % of resistant isolates
50% 90%
VanA and VanB strains Daptomycin 4 8 Not determined
Linezolid 2 2 1.5
Quinupristin/dalfopristin 0.5 1 6.0
Ampicillin 64 128 93.2
Doxycycline 4 16 14.2
Vancomycin > 128 > 128 100
VanC1 and VanC2 strains Daptomycin 1 2 Not determined
Linezolid 2 2 0
Quinupristin/dalfopristin 2 2 0
Ampicillin 0.5 1 0
Doxycycline ≤ 0.25 ≤ 0.25 4.5
Vancomycin 4 4 0
eISSN:
2545-3149
Languages:
English, Polish
Publication timeframe:
4 times per year
Journal Subjects:
Life Sciences, Microbiology and Virology